Abstract
Prescription drug abuse, especially the illegal use of opiates such as Oxycontin®, has reached epidemic proportions in the United States. Patients who are opiate dependent can be very challenging to care for. Chronic opiate use significantly alters neurophysiology and limits the effectiveness of many anesthetic medications. Similarly, many of the agents now used to attempt to detoxify patients may also alter anesthetic responsiveness. A detailed knowledge of the pharmacology of the agents used to maintain and detoxify addicts is essential for successful perioperative management of these challenging patients.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Raisch DW, Fye CL, Boardman KD, Sather MR. Opioid dependence treatment, including buprenorphine/naloxone. Ann Pharmacother. 2002;36:312–21.
Ling W. Buprenorphine for opioid dependence. Expert Rev Neurother. 2009;9(5):609–16.
National Survey on Drug Use and Health, 2005. Rockville, MD, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. 2006. Available at www.icpsr.umich.edu/cocoon/ICPSR/STUDY/04596.xml.
The Determinations Report: A Report on the Physician Waiver Program Established by the Drug Addiction Treatment Act of 2000 (“DATA”). Rockville, MD: Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment; 2006.
Patient Brochure. Suboxone Facts for Patients. Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc; 2008. p. 23235.
Orman JS, Keating GM. Buprenorphine/Naloxone: a review of its use in the treatment of opioid dependence. Drugs. 2009;69(5):577–607.
Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend. 2003;70 Suppl 1:S87–101.
Michel E, Zernikow B. Buprenorphine in children. A clinical and pharmacological review. Schmerz. 2006;20:40–50.
Geib AJ, Babu K, Burns M, et al. Adverse effects in children after unintentional buprenorphine exposure. Pediatrics. 2006;118:1746–51.
Hand CW, Sear JW, Uppington J. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br J Anaesth. 1990;64:276–82.
Berson A, Gervais A, Cazals D, et al. Hepatitis after intravenous buprenorphine misuse in heroin addicts. J Hepatol. 2001;34:346–50.
Petry NM, Bickel WK, Piasecki D, et al. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict. 2000;9:265–9.
Jones HE, Johnson RE, Milio L. Post-cesarean pain management of patients maintained on methadone or buprenorphine. Am J Addict. 2006;15(3):258–9.
Book SW, Myrick H, Malcolm R, Strain EC. Buprenorphine for postoperative pain following general surgery in a buprenorphine-maintained patient. Am J Psychiatry. 2007;164:979.
Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med. 2006;144(2):127–34.
Robert DM, Meyer-Witting M. High-dose buprenorphine: perioperative precautions and management strategies. Anaesth Intensive Care. 2005;33:17–25.
Schuh KJ, Walsh SL, Stitzerr ML. Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans. Psychopharmacology. 1999;145:162–74.
Welsh C, Sherman SG, Tobin KE. A case of heroin overdose reversed by sublingually administered buprenorphine/naloxone (Suboxone®). Addiction. 2008;103:1226–8.
Totah R, Sheffels P, Robert T, et al. Role of CYP2B6 in steroselective human methadone metabolism. Anesthesiology. 2008;108:363–74.
Mahajan G, Fishman SM. Opioids in Pain Management. In: Benzon HT, editor. Essentials of pain medicine and regional anesthesia. 2nd ed. Philadelphia, PA: Elsevier; 2005. Major Chapter 11.
Sims SA, Snow LA, Porucznik CA. Surveillance of Methadone related adverse drug events using multiple public health data sources. J Biomed Inform. 2007;40:382–9.
Glajchen M. Chronic pain: treatment barriers and strategies for clinical practice. J Am Board Fam Pract. 2001;14:211–8.
Zanger UM, Klein K, Saussele T. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics. 2007;8:743–59.
Peng PW, Tumber PS, Gourley D. Review article: perioperative pain management of patients on methadone therapy. Can J Anaesth. 2005;525:513–23.
Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J. Treatment of acute opioid withdrawal with ibogaine. Am J Addict. 1999;8(3):234–42.
Mash DC, Kovera CA, Pablo J, et al. Ibogaine in the treatment of heroin withdrawal. Alkaloids. 2001;56:155–71.
Hoelen DW, Spiering W, Valk GD. Long-QT syndrome induced by the antiaddiction drug ibogaine. N Engl J Med. 2009;360(3):308–9.
Alper KR, Lotsof HS, Kaplan CD. The ibogaine medical subculture. J Ethnopharmacol. 2008;115(1):9–24.
Mattick RP, Breen C, Kinbler J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;8(3):CD002209.
Kaye AD, Banister RE, Hoover JM, et al. Chronic pain and ultra rapid opioid detoxification. Pain Physician. 2005;5(1):33–42.
Shader RI. Antagonists, inverse agonists, and protagonists. J Clin Psychopharmacol. 2003;23(4):321–2.
Therapeutic Goods Administration. “Australian Register of Therapeutic Goods Medicines” (Online database of approved medicines). https://www.ebs.tga.gov.au/ebs/ANZTPAR/PublicWeb.nsf/cuMedicines?OpenView. Accessed 11 May 2010.
Latt NC, Jurd S, Houseman J, Wutzke SE. Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust. 2002;176(11):530–4.
Heinälä P et al. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind placebo-controlled trial. J Clin Psychopharmacol. 2001;21:287–92.
O’Malley SS, Jaffe A, Chang G, Witte R, et al. Naltrexone in the treatment of alcohol dependence. In: Reid LD, editor. Opioids, bulimia, and alcohol abuse and alcoholism. New York, NY: Springer; 1990.
National Institutes of Health. Naltrexone or specialized alcohol counseling an effective treatment for alcohol dependence when delivered with medical management. Press release; May 2, 2006.
Sinclair JD. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol. 2001;36(1):2–10.
Schmitz J, Stotts A, Rhoades H, Grabowski J. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav. 2001;26(2):167–80.
Anton R, Oroszi G, O’Malley S, et al. An evaluation of opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence. Arch Gen Psychiatry. 2008;65(2):135–44.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Gevirtz, C., Bryson, E.O., Frost, E.A.M. (2012). Pharmacologic Treatments for Addiction. In: Bryson, E., Frost, E. (eds) Perioperative Addiction. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-0170-4_3
Download citation
DOI: https://doi.org/10.1007/978-1-4614-0170-4_3
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-0169-8
Online ISBN: 978-1-4614-0170-4
eBook Packages: MedicineMedicine (R0)